Cross-Border Impact Ventures invests in transformative health technology companies addressing large global markets in women, children and adolescent health.
CrossBorder Investment Ventures (CBIV) receives a nomination for the 2026 Prix Galien USA Award. The venture fund highlights its second fund’s success, including portfolio exits and measurable impact in women’s and children’s health innovation. Institutional investors continue to back CBIV’s focus on global health solutions.
Cross-Border Impact Ventures announces a US$58 million first close of its second health technology fund. The Toronto impact firm says returning institutional investors are backing the vehicle, which targets companies focused on women's and children's health.
Cross-Border Impact Ventures wins the Best HealthTech Investment Company 2024 award for Canada. Wealth and Finance International names the Toronto impact firm the winner, citing its gender-lens health technology strategy.
Managing partner Annie Theriault discusses Cross-Border Impact Ventures’ investment thesis, first-fund close, and why impact investors participate in early commercialization rounds for women’s and children’s health technologies. The conversation also covers the firm’s focus on transformative health companies serving women and children.
May 2024Pulse 2.0News article
Cross-Border Impact Ventures
Impact venture firm backing health technologies for women, children, and adolescents.
